



Proteomics



The **Proteome** indicates the **proteins** expressed by the **genome** or tissue





Thousands of proteins can be reproducibly separated on one 2D gel from ~1mg of tissue/biopsy or biological fluid.



Automation and robotics; Spot picker




Automation of digestion by robotics




Enhanced spot detection

- Detects spots on the internal standard
- Detects spots unique to rest of multiplex
- Propagates this map to all images within the group
- Independently grows out spot boundaries
- Ensures exact and accurate definition of each spot on each gel
- Maintains multiplex group consistency





ProPic Spot picking robot


The ProPic cuts protein spots of interest and deposits gel plugs into a 96 well plate




ProPic Spot picking robot




Sample 1 (ISTD)



label with cy2
in dark 30mins @ 4°C




Sample 2




label with cy3
in dark 30mins @ 4°C




Sample 3



label with cy5
in dark 30mins @ 4°C



quench un-reacted dye
by adding 1mM lysine
in dark 10mins @ 4°C




Difference Gel Electrophoresis

- Ünlü M. *et al* (1997). *Electrophoresis*, 18, 2071-2077

2D gel electrophoresis
on same gel

Overlay Analysis -Image at different wavelengths on a Storm or Typhoon imaging system (GE Healthcare)



no difference



presence / absence




up / down-regulation






Detection sensitivity of gel staining methods

Staining method	Protein detection limit	Compatibility with MS
Silver + glutaraldehyd	1-10 ng	-
Silver	10 ng	+/-
Coomassie R-250	>100 ng	+
Coomassie G-250	>30 ng	+
Negative Zn-imidazole	>100 ng	+
SYPRO Orange	>30 ng	+
SYPRO Ruby	>10 ng	+



Some proteins are more sensitive to particular stains






14-3-3 and neurodegenerative diseases



14-3-3 proteins in neurodegenerative disease

2D-gel electrophoresis of Spinal Fluid from CJD patient (silver stained) From: Zerr *et al*, Lancet, 348, 846-9, 1996



14-3-3 in Neurodegenerative Disease



1. **Prion diseases:** (a) 14-3-3s are novel biochemical markers in cerebrospinal fluid (CSF) of patients with neurodegenerative diseases.

Although six isoforms expressed in brain we showed that only four of these isoforms (β , ϵ , γ & η) are present in CSF of sporadic CJD patients but not in healthy subjects

(b) Specific isoforms of 14-3-3 also appear in CSF of sheep with scrapie and cows with BSE. Another subset of isoforms is present in CSF of patients with a range of other neurodegenerative diseases including **14-3-3 η** in **Alzheimer's disease** patients.


(Wiltfang *et al*. J Neurochem 73 (1999).

2D-gel electrophoresis of Spinal Fluid from CJD patient (silver stained) From: Zerr *et al*, Lancet, 348, 846-9, 1996




2. Protein-protein interactions and the overlay technique

1. Digoxigenin-labelled 14-3-3 γ interacting with PVDF membrane-bound protein




Interacting protein

2. + anti-digoxigenin Fab fragments conjugated with alkaline phosphatase (AP)



Dig-labelled 14-3-3 γ

3. + substrate for the reaction with AP (X-phosphate, NBT)




Anti-Dig-AP

Colour reaction

8


Protein-protein interactions and the overlay technique




Proteins were run on a 12% (w/v) SDS-polyacrylamide gel, transferred to nitrocellulose and probed with digoxigenin labelled (DIG-) 14-3-3 (c) DIG-14-3-3 overlays of dephosphorylated proteins, indicating alignment of bands in a crude soluble extract and 14-3-3 column eluate. Lane 1, 14-3-3 column eluate (5 μ l) was incubated with purified bovine protein phosphatase 2A at 50 mU ml⁻¹ for 30 min at 30°C and dephosphorylation stopped with the protein phosphatase inhibitor, microcystin-LR (2 μ M) prior to electrophoresis. In lane 2, the microcystin-LR (2 μ M final) was added to the protein phosphatase 2A prior to incubation with the 14-3-3 column eluate. The bands in the 14-3-3 column eluate (lane 2) are compared with a crude extract (lane 3). The slight



Protein-protein interactions and the overlay technique


Separation and identification of DIG labelled 14-3-3 interacting proteins




Moorhead et al Phosphorylation-dependent interactions between enzymes of plant metabolism and 14-3-3 proteins. Plant J. 1999 18, 1-12.









14-3-3 protein complexes in neurodegenerative disease



14-3-3 protein complexes in neurodegenerative disease



14-3-3 protein complexes in neurodegenerative disease



14-3-3 in Neurodegenerative Disease

3. Polyglutamine repeat diseases:

Nine known neurodegenerative diseases caused by CAG repeat expansion resulting in proteins containing a greatly expanded polyglutamine (polyQ) stretch; from approximately 20 glutamines in normal individuals to over 40 in affected individuals.

The mutant proteins are unrelated except for the polyQ tract.


(a) Spinocerebellar ataxia type-1 (SCA1):

14-3-3 ζ and ϵ stabilize phosphorylated **ataxin-1** which accumulates in neurons, inducing neurodegeneration (Chen et al, 2003, Cell 113, 457-468).

(b) Dentatorubral-pallidoluysian atrophy

(**DRPLA**): **atrophin-1**, IRSp53 and 14-3-3 interact (Mackie & Aitken, 2005 "Novel brain 14-3-3 interacting proteins involved in neurodegenerative disease". FEBS J, 272, 4202-4210).

(c) **Huntington's disease**: (others have more recently shown that 14-3-3 associates with phosphorylated **huntingtin**).



Colocalisation and stabilisation of ataxin-1 with 14-3-3 ϵ


Interaction of Akt-Phosphorylated Ataxin-1 with 14-3-3 Mediates Neurodegeneration in Spinocerebellar Ataxia Type 1: (Chen et al Cell, 2003).

Spinocerebellar ataxia type 1 (SCA1) is one of several neurological disorders caused by a CAG repeat expansion. In SCA1, this produces an abnormally long polyGln tract in **ataxin-1**.


Mutant polyGln proteins accumulate in neurons, inducing neurodegeneration. 14-3-3 mediates neurotoxicity of ataxin-1 by binding to and stabilizing ataxin-1, thereby slowing its normal degradation.

Association of ataxin-1 with 14-3-3 ζ and ϵ is regulated by Akt phosphorylation on residue 776:

RRWS^PAP.



The ICAT strategy for quantifying differential protein expression.



Structure of the ICAT reagent, which is in two forms, heavy (8 deuteriums) and light (no deuterium).


The reagent has three elements:

- an affinity tag (biotin), to isolate ICAT-labeled peptides
- a linker that can incorporate stable isotopes
- a reactive group with specificity toward thiol groups (cysteines)


The ICAT strategy for quantifying differential protein expression.

Two protein mixtures representing two different cell states treated with the isotopically light and heavy ICAT reagents; an ICAT reagent is covalently attached to each cysteinyl residue in every protein. The protein mixtures are combined, proteolyzed and ICAT-labeled peptides are isolated on an avidin column utilizing the biotin tag.


Peptides are separated by HPLC. A pair of ICAT-labeled peptides are chemically identical and are easily visualized because they essentially coelute, and there is an 8 Da mass difference measured in a scanning mass spectrometer (four m/z units difference for a doubly charged ion). The ratios of the original amounts of proteins from the two cell states are strictly maintained in the peptide fragments. The relative quantification is determined by the ratio of the peptide pairs. The protein is identified by database searching with the sequence information.



Schematic of ICAT Method




SILAC



Stable isotope labelling with amino acids in cell culture (SILAC) is a simple and straightforward approach for in vivo incorporation of a tag into proteins for relative quantitation by mass spectrometry.

$^{12}\text{C}_6^{14}\text{N}_4\text{-Arg}$, $^{13}\text{C}_6^{14}\text{N}_4\text{-Arg}$ and $^{13}\text{C}_6^{15}\text{N}_4\text{-Arg}$ isotopically labelled amino acids can be used.


^{12}C - and ^{13}C - labelled leucine also used.




Applied Biosystems iTRAQ Reagents are a set of **four, isobaric (same mass) reagents** which are amine specific and yield labelled peptides which are identical in mass and hence also identical in single MS mode, but which produce strong, diagnostic, low-mass MS/MS signature ions allowing for quantitation of up to four different samples simultaneously. This gives:

- **Analysis of up to four different biological samples** in a single experiment (or **triplicate analyses** of the same sample).
- **Absolute quantitation** across numerous sample states, for the uniform comparison of normal, diseased and/or drug treated states.
- Information such as **post-translational modifications** which is not lost using this new chemistry.
- Since all peptides are tagged, proteome coverage is expanded and analysis of multiple peptides per protein improves the confidence and quantitation.
- Protein identification is simplified by improved fragmentation patterns, with no signal splitting in either the MS or MS/MS therefore low-level analysis is enhanced as a result of the signal amplification.
- The complexity of MS and MS/MS data is not increased by mixing multiple proteome samples together.

iTRAQ Reagent Structure



iTRAQ Reagents are isobaric tagging reagents consisting of: a **reporter group**, a **balance group**, and a **peptide reactive group**. The **peptide reactive group** covalently links an iTRAQ Reagent isobaric tag with each lysine side chain and N-terminus of a peptide, labelling all peptides in a given sample digest.





Combining multiple iTRAQ Reagent labelled digests into one sample mixture, the MS resembles the MS of an individual sample (assuming the same peptides are present).

The **balance group** ensures that an iTRAQ reagent-labelled peptide displays the same mass, whether labelled with iTRAQ reagent 114, 115, 116, or 117.

During MS/MS (along with the usual peptide fragmentation) the isobaric tag cleaves at the sites indicated:

As a result of fragmentation, there is neutral loss of the balance group, and the reporter groups are generated, displaying diagnostic ions in the low-mass region between m/z of 114-117. Because this region is free of other common ions, quantifying the peak areas of these resultant ions represents the relative amount of a given peptide in the respective sample.

These diagnostic ions are the key components in quantitative experiments.





Antarctic Prion *Pachyptila desolata*



Slender-billed Prion